Zastaprazan

Zastaprazan
Clinical data
Trade namesJaqbo
Other namesJP-1366
ATC code
Legal status
Legal status
  • KR: Rx-only
Identifiers
  • azetidin-1-yl-[8-[(2,6-dimethylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC22H26N4O
Molar mass362.477 g·mol−1
3D model (JSmol)
  • CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4
  • InChI=1S/C22H26N4O/c1-14-7-5-8-15(2)19(14)12-23-20-11-18(22(27)25-9-6-10-25)13-26-17(4)16(3)24-21(20)26/h5,7-8,11,13,23H,6,9-10,12H2,1-4H3
  • Key:FEQFUBYYZYQTOJ-UHFFFAOYSA-N

Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker. In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.